Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Cell Medica Announces Senior Management Appointments

Published: Friday, March 08, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
Key appointments to Cell Medica's senior executive team.

Cell Medica has announced key appointments to its senior executive team.

The strengthened management team will enable Cell Medica to broaden its product development activities, particularly in the US, and will support further international growth.

Dr. Kurt Gunter joins Cell Medica as Chief Medical Officer and will have a senior role in managing the clinical and regulatory aspects of the Company’s therapeutic products with a focus on the cancer immunotherapy program.

As Chief Financial Officer, Jeff Hammel will be responsible for Cell Medica’s global financial and business management systems to drive the continued growth of Cell Medica’s commercial operations in both Europe and the US.

Ross Durland, PhD, has joined as Senior Vice President Development with global responsibility for product development activities.

Ross will focus on the Company’s pipeline strategy while also assisting in setting up the manufacturing operations in the US.

The new members of the executive team will be based in Cell Medica’s recently established US office in Houston, Texas and will have global responsibility for their respective functions.

Also joining the Houston office are Cynthia Molina, Senior Director Regulatory Affairs and Shannon Inman, Director Clinical Operations, each with regional responsibility for the US.

Gregg Sando, CEO of Cell Medica, commented, “Expanding our management team with such experienced biotech professionals is a crucial step as we extend our operations to the US market. For Cell Medica, this represents an important growth milestone in our strategy to build an industry leader in cellular therapeutics on a global basis.”

Dr. Kurt Gunter, Chief Medical Officer
Kurt has devoted his career to the development of cell and gene therapies and brings significant commercial experience to Cell Medica from his previous positions at Hospira, ViaCell and Transkaryotic Therapies.

As current President of the International Society for Cellular Therapy (ISCT), Kurt plays a worldwide leadership role in promoting the understanding of the clinical, regulatory, manufacturing and marketing requirements for the successful development of cell and gene therapies.

Prior to his biotech career, he worked at the U.S. Food and Drug Administration as a Medical Officer and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research (CBER).

Jeff Hammel, Chief Financial Officer
Jeff joins Cell Medica with over 17 years of broad financial and operational experience in the healthcare industry. In his previous role as Chief Financial Officer for the largest operating division of Orthofix International NV, Jeff managed the global financial operations for a medical technology business with $300 million revenues across all major international markets.

Jeff played an active role in providing financial and analytical support to manage strategic and operational goals. He was also a key member of the integration team for a significant acquisition.

Prior to Orthofix, Jeff spent eight years at the head office of Eli Lilly & Company where his final position was US Controller for the $7.0 billion US pharmaceutical division.

Ross Durland, Senior Vice President Development
Ross has over 20 years of experience in the development of highly innovative therapeutic products and technologies. He gained significant experience with cell-based therapeutics while at Valentis (formerly GeneMedicine; The Woodlands, TX) where he rose to Senior Director Preclinical Development and led multi-site, multidisciplinary product development teams advancing two new gene therapy products from animal proof-of-concept to human clinical testing.

During his time at Valentis, Ross also participated in developing five additional clinical stage products, and led the company’s manufacturing and quality control functions in manufacturing products for preclinical and clinical testing.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cell Medica Announces Treatment of First Pediatric Patient in ASPIRE Trial
ASPIRE Trial expected to complete in early 2015.
Tuesday, July 09, 2013
Cell Medica Secures £17 Million Equity Investment
Investment to establish US operations and fund cell therapy development.
Monday, August 06, 2012
Cell Medica and UCL Institute of Child Health Receive Grant Funding
Company receives grant funding from the Technology Strategy Board for ASPIRE.
Monday, March 05, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos